These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [SSRI antidepressant use during pregnancy and the assessment of the risk-benefit ratio].
    Author: Weisskopf E, Fumeaux CJ, Bickle Graz M, Harari MM, Epiney M, Tolsa CB, Rouiller S, Tolsa JF, Eap CB, Vial Y, Csajka C, Panchaud A.
    Journal: Rev Med Suisse; 2016 Mar 16; 12(510):561-6. PubMed ID: 27149719.
    Abstract:
    Studies report that between 6 and 13% of women experience symptoms of depression during pregnancy and the postpartum period. The abundant data available make selective serotonin reuptake inhibitors (SSRIs) the first line treatment in pregnancy when a pharmacological treatment is required. Risks associated with the use of SSRIs during pregnancy are limited (moderate effect size) and are often not distinguishable from those inherent to the mother's disease. Yet, several questions regarding the SSRI safety profile for the unborn child are still under debate or require additional epidemiological data. The decision of SSRI use during pregnancy needs an individual evaluation of the risk-benefit balance.
    [Abstract] [Full Text] [Related] [New Search]